| Popis: |
Margaret Noyes Essex,1 Hao Xu,2 Bruce Parsons,1 Li Xie,3 Chunming Li4 1Global Medical Affairs, Pfizer, New York, NY, USA; 2Department of General Surgery, Jiangsu Province Hospital, Nanjing, China; 3Medical Affairs, Pfizer Investment Co. Ltd., Beijing, China; 4Statistics, Pfizer, Madison, NJ, USA Purpose: Parecoxib provides analgesia following a variety of surgeries, including minor gastrointestinal procedures. To our knowledge, there is no data on parecoxib following major gastrointestinal surgery. This study assessed the efficacy and opioid-sparing effects of parecoxib following major gastrointestinal surgeries. Patients and methods: Patients in this analysis were a subset from a large, randomized, double-blind, placebo-controlled trial of parecoxib following noncardiac surgeries and consisted of those undergoing a variety of major gastrointestinal surgeries via laparotomy. Pain, pain interference with function, supplemental opioid utilization, opioid-related symptoms, and Patient/Physician Global Evaluation of Study Medication were compared between placebo and parecoxib groups in the 2−3 days following surgery. Results: Significantly (p |
